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ABSTRACT
Glioblastomas are the most common malignant brain tumor, with an annual incidence of
6 in 100,000 people. Conventional treatment modalities, including chemotherapy and
radiation, are toxic and cause a decrease in quality of life as the disease progresses.
Several investigators have turned to pharmacologically active derivatives of herbal
remedies as less-toxic alternatives. Indirubin, a dark red isomer of indigo, is known to be
effective in treating chronic inflammation and some forms of cancer, and the mechanism
is, in part, due to activity as a ligand for the transcription factor aryl hydrocarbon receptor
(AhR). As with most AhR ligands, indirubin induces the CYP1 family of metabolizing
enzymes, alters cell cycling, and can be active through the GSK-3β pathway. In recent
years, bioavailable derivatives have been synthesized, including indirubin-3’-(2,3
dihydroxy-propyl)-oximether (E804). Several lines of research show that E804 has antiangiogenic and anti-proliferative properties, and we previously demonstrated antiinflammatory properties of E804. In this study, T98G human glioblastoma cells were
treated with E804 to determine the degree of AhR activation, the secretion of both
immunosuppressive and pro-inflammatory cytokines by the tumor cells, and the effects of
those tumor secretions on macrophage polarization. E804 is potent inducer of CYP1B1 in
T98G cells, has modest effects on TGFβ2 secretion, and suppresses VEGF at high does,
while enhancing VEGF secretion at low doses. The secretion of IL-6 by T98G cells was
only modestly affected at the highest treatment levels. The effects of supernatants derived
from E804-treated T98G cells on macrophage indicate that E804 may polarize
macrophages to the pro-tumor M2 phenotype. Overall, the results of this study indicate
ii

that E804 concentrations would need to be carefully monitored in a clinical application.
Future studies should include an in vivo model of brain tumors to test the potential of
E804 as a standalone, or adjuvant treatment for glioblastoma.
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CHAPTER ONE
LITERATURE REVIEW
BRAIN TUMORS AND CURRENT TREATMENT MODALITIES
Brain tumors are among the most dreaded diagnosis in oncology. Brain and
central nervous system cancers are the number one cause of cancer-related death in
children 0-14, and the third leading cause in adolescents 15-19 according to the National
Center for Health Statistics for 2014 (SEER, 2010). In general, prognosis is poor and
there are few treatment options. Tumors that originate in the brain are similar to other
cancers in many ways, but also provide their own unique challenges. All cancer cells
possess certain key traits: sustained growth signals, evasion of growth suppressors,
activation of invasion and metastasis, induction of angiogenesis, resistance to cell death,
evasion of the immune system, and the dysregulation of cellular energetics (as reviewed
by (Hanahan and Weinberg, 2011). However, brain tumors are especially difficult for
patients and care providers to manage (Schwartzbaum et al., 2006). Depending on the
location and size of the tumor, patients can experience personality and mood shifts,
severe headaches, seizures, and loss of senses, memory, coordination or bodily control
(SEER, 2010). These symptoms are compounded by the fact that the brain is enclosed in
a hard shell, the skull. Growth of tissue in one area can cause pressure and swelling of
other areas, pushing against the skull, causing severe pain and even brain damage (Figure
1). Tumors within the brain are also inherently more difficult to treat (Schwartzbaum et
al., 2006). Surgery is not always an option due to the location of the tumor, but even if it
is possible, there are many risks involved, including damage to other areas of the brain
1

(Omuro, 2013; Schwartzbaum et al., 2006). Radiation treatment can also quickly damage
healthy regions. Chemotherapeutic drugs must be able to access the tumor, which can be
challenging if the blood-brain barrier is still intact (Schneider et al., 2004). Brain tumors
also tend to be more chemo-resistant than other forms of cancer (Adams et al., 2012). In
this way, brain tumors, particularly rapidly growing types, such as glioblastoma, have the
ability to completely incapacitate an individual.
Glioblastoma (WHO grade IV) is a highly malignant, lethal form of brain cancer.
Glioblastomas are the most common form of gliomas, which account for approximately
80% of malignant brain tumors (Schwartzbaum et al., 2006), but their precise causes
remain unknown. Glioblastomas are composed of a mixture of astrocytes, supportive
star-shaped cells in the central nervous system, and endothelial cells (Omuro, 2013).
Secondary finger-like structures are usually found away from the primary tumor (Paw et
al., 2015). Tumor cells are capable of traveling down myelinated nerves and following
the basement membrane of blood vessels, particularly within Virchow-Robins spaces
(Pedersen et al., 1995). Virchow-Robins spaces are part of the subarachnoid and sub-pial
space below the meninges which surround blood vessels that enter the brain (Pedersen et
al., 1995). In these areas, the hydrostatic pressure of cerebral spinal fluid allows cells to
move quickly, spreading far beyond the primary tumor (Pedersen et al., 1995). This
invasive growth pattern makes glioblastomas nearly impossible to completely remove
surgically (Giese, 2003). However, current treatment modalities usually begin with
surgical removal of the majority of the tumor to relieve pressure on the surrounding
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tissue, if the tumor is in an operable location. This also allows for more precise
histological grading of the tumor (Omuro, 2013).
Following resection, first line treatments involve radiation therapy, chemotherapy,
or a combination of the two. In glioblastoma and other progressed brain tumors, the blood
brain barrier is often degraded, letting drugs more freely access the central nervous
system (Schneider et al., 2004). Common chemotherapy agents include the DNA
alkylating agents temozolomide (TMZ), carmustine, and lomustine (Omuro, 2013). After
surgical removal of the majority of the tumor, carmustine-loaded chips called Gliadel®
wafers can be implanted directly into the brain (Perry, 2007). These drugs, like all
chemotherapy, are toxic and can have severe side effects, including impaired immune
system function, nausea, vomiting, hypertension, and hematologic toxicity, such as
anemia (Omuro, 2013; Perry, 2007). Newer treatments include a monoclonal antibody
against vascular endothelial growth factor (VEGF) called bevacizumab (Avastin®)
(Reardon et al., 2014). Bevacizumab inhibits angiogenesis, reducing the tumor’s ability
to grow new blood vessels, limiting its size (Reardon et al., 2014). However, this
treatment could also lead to hypertension, wound healing delays, venous or arterial
thrombosis, and hematologic toxicity, among other side effects (Omuro, 2013; Reardon et
al., 2014). With treatment, median 2 year survival rate for glioblastoma patients remains
between approximately 2-30%, depending on age at diagnosis (Schwartzbaum et al.,
2006). Clearly, less toxic, more effective treatments are needed. For these alternatives,
many researchers are looking to natural sources.

3

Figure 1: WHO grade IV glioma, American Journal of Neuroradiology, submitted by
Jason McKellop, Amir Paydar, Girish Fatterpekar, Alexander Baxter, NYU Langone
Medical Center, New York, NY. http://www.ajnr.org/site/com/2012jun.xhtml
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INDIRUBINS AND THE ARYL HYDROCARBON RECEPTOR
Medicinal herbs and plants have been used for centuries to treat various ailments,
including cancer. One such Chinese remedy is Danggui Longhui Wan, a mixture of 11
herbs used to treat chronic myelocytic leukemia and other inflammatory diseases
(Hoessel et al., 1999). After extensive research, the active compound in Danggui Longhui
Wan was found to be a red isomer of the blue dye indigo, called indirubin (Hoessel et al.,
1999). Indirubin has been shown to slow or stop cell proliferation by inducing cell cycle
arrest and apoptosis via cyclin dependent kinases (CDKs) (Hoessel et al., 1999) and
glycogen synthase kinase-3β (GSK-3β) (Xie et al., 2004). Naturally occurring indirubin
is not very bioavailable, so researchers have synthesized artificial indirubin derivatives
(Moon et al., 2006). These derivatives vary in in the location and composition of their
side chains, which alter their receptor binding affinity and, therefore, their downstream
effects (Moon et al., 2006). One such derivative is indirubin-3’-(2,3 dihydroxypropyl)oximether (E804). E804 has been shown inhibit STAT3 and induce apoptosis in multiple
human cancer cell lines (Nam et al., 2005b). E804 also has strong anti-inflammatory and
anti-angiogenic properties, but the precise mechanism of this action remains unclear
(Anderson, 2014; Chan et al., 2012). One known pathway is through interaction with the
aryl hydrocarbon receptor.
The aryl hydrocarbon receptor (AhR), a transcription factor of the family helixloop-helix, has been heavily studied since its link to 2,3,7,8-tetrachlorodibenzo-p-dioxin
(TCDD) toxicity in the 1970’s (Poland, 1976). The activation of AhR has been linked to
several pathways, ranging from carcinogenesis (Andersson et al., 2002) to tumor
5

therapies (Koliopanos et al., 2002), depending on the strength of the ligand binding. The
stronger the binding of a ligand to the AhR, the more toxic and long lasting its effects
seem to be. Indirubins have been shown to interact with AhR in varying degrees
(Knockaert et al., 2004), but their interactions are brief due to the compounds’
metabolism by cytochrome P450 enzymes like CYP1A1 and CYP1B1 (Spink et al.,
2003). Thus, indirubins that bind strongly, but transiently, to AhR may have potent antiinflammatory and anti-tumor properties without the side effects of more stable ligands
like TCDD (Chan et al., 2012; Knockaert et al., 2004).

INFLAMMATION AND IMMUNE RESPONSE
Inflammation is a complex bodily response to tissue damage or pathogen
intrusion. Local acute inflammation is beneficial in destroying these invaders, but a
chronic or inappropriate inflammatory response can damage healthy tissue and cause
severe pain (Coussens and Werb, 2002). Chronic inflammation has also been shown to
contribute to many aspects of cancer initiation, promotion, and metastasis (Coussens and
Werb, 2002). After an injury occurs, damaged cells release chemokines that attract
monocytes, which differentiate into macrophages in tissue, and aid in wound repair
(Coussens and Werb, 2002). Similarly, when a tumor begins to form, the transformed
glial cells release chemokines that activate and attract immune cells from within the CNS,
called microglia, and macrophages from outside the CNS (Bingle et al., 2002; Ransohoff
et al., 2015). However, rather than destroying the cancerous cells, the macrophages’
6

function is suppressed within the tumor microenvironment (Kennedy et al., 2013). These
tumor-associated macrophages and microglia (TAMs) quickly accumulate, and can
compose 30 to 40 percent of the tumor’s volume (Kennedy et al., 2009). It has also been
shown that the number of infiltrating macrophages positively correlates with the
histological grade of the tumor (Nishie et al., 1999).
There are two main lineages of TAMs; M1, which are inflammatory and capable
of killing cancer cells, and M2, which suppress immune function (Kennedy et al., 2013).
The M1 versus M2 phenotype can be distinguished through genetic and cytokine
secretion profiling (Kennedy et al., 2013). M2 type TAMs are thought to suppress
inflammation though interleukin 10 (IL-10) and transforming growth factor beta (TGF-β)
secretion (Mantovani et al., 2002). Interleukin-6 (IL-6) has been shown to have both proand anti-inflammatory properties, as well as being implicated in increased angiogenesis
and tumor metastasis (Liu et al., 2010). The M2 divergence also leads to increased VEGF
release from tumor cells (Kennedy et al., 2013). During this progression, the tumor cells
are releasing their own cytokines and growth factors, which can equal or exceed those
produced by activated macrophages (Ulvestad et al., 1994). Interplay between the TAMs
and tumor cells is also seen, which can feed each other’s secretion in a paracrine and
autocrine method (Kennedy et al., 2013). Other proteins can also effect M1 versus M2
polarization, such as arginase 1 and 2 (ARG1, ARG2), indoleamine 2,3-dioxygenase 1
(IDO1), cyclooxygenase-2 (COX-2) (Barksdale et al., 2004; Iachininoto et al., 2013; Ino
et al., 2013; Mellor and Munn, 2004).
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The enzyme arginase catalyzes hydrolysis of L-arginine to L-ornithine and urea
(Barksdale et al., 2004). There are two isomers of arginase, ARG1 and ARG2 (Bronte et
al., 2003; Ino et al., 2013). Depletion of arginine within a given environment can reduce
the expression of the CD3 ζ chain on cytotoxic (CD8+) T-cells, preventing the T-cell
receptor from interacting with the major histocompatibility complex (MHC), resulting in
T-cell anergy (Zea et al., 2005). Arginine is also necessary for nitric oxide (NO)
synthesis, which is required for proper T-cell function (Barksdale et al., 2004). Increased
ARG1 activity is one of the most well-defined markers of M2 polarization in mice, but
ARG1 is only found in granulocytes in humans (Sica and Bronte). It has been shown that
renal carcinoma granulocytes in humans may be acting through a similar mechanism as
M2-polarized macrophages (Zea et al., 2005). ARG1 is also known to be induced by
TGF-β, another cytokine implicated in immune suppression (Bodmer et al., 1989; Bronte
et al., 2003). Alternatively, ARG2 is found in the mitochondria of most human cells,
including monocytes. ARG2 is involved in the synthesis of polyamines and has been
shown to be induced by IL-10 (Barksdale et al., 2004). Increased levels of ARG2 has
been seen in macrophages isolated from patients with multiple sclerosis (MS) (Barksdale
et al., 2004). However, linkage to cancer progression and severity depends on tissue type
(Ino et al., 2013; Rotondo et al., 2008). Increased ARG2 expression has been found to
correlate with poor prognosis in patients with pancreatic or prostate cancer, but not lung
cancer (Ino et al., 2013; Rotondo et al., 2008).
The enzyme IDO1 is responsible for the breakdown of L-tryptophan to
kynurenines (KYN) (Iachininoto et al., 2013). An increase in KYN within a
8

microenvironment promotes FoxP3+ regulatory T-cell (Treg) activity, suppressing T-cell
and dendritic cell responses (Iachininoto et al., 2013; Mellor and Munn, 2004). High
levels of IDO1 has also been correlated with poor prognosis in patients with acute
myeloid leukemia and certain solid tumors (Chamuleau et al., 2008). COX-2 is one of the
two isoforms of the cyclooxygenase enzyme responsible for prostaglandin synthesis
(Iachininoto et al., 2013; Minghetti, 2004). COX-2 is also a main cause of inflammationassociated pain in the central nervous system, and the target of non-steroidal antiinflammatory drugs (NSAIDs) (Minghetti, 2004; Samad et al., 2001; Wang and DuBois,
2009). Inhibition of COX-2 activity has been shown to suppress the activity Treg cells,
promoting the destruction of lung cancer cells (Sharma et al., 2005). Both IDO1 and
COX-2 are produced by human macrophages, and induced by interferon gamma (IFN-γ),
which has been implicated in both pro- and anti-tumor pathways (Iachininoto et al., 2013;
Zaidi and Merlino, 2011).
The understanding of the cytokine and growth factor profile of a given tumor is
critical to proper treatment, and can shape the approach taken, particularly when
considering immunotherapy (Reardon et al., 2014; Zea et al., 2005). The particularly
immunosuppressive nature of the glioblastoma microenvironment has been cited as the
source of struggle in the development of successful immune therapies, but recent
advances have shown promise (Reardon et al., 2014). There are currently many clinical
trials being conducted on immunotherapeutic options, including combinations of
traditional chemotherapies with monoclonal antibodies, such as ipilimumab and
tremilimumab (Reardon et al., 2014).
9

CHAPTER TWO
EFFECTS OF THE INDIRUBIN DERIVATIVE E804 ON GLIOBLASTOMA
ASSOCIATED IMMUNOMODULATION
INTRODUCTION
Because of their location and quick growth, brain and central nervous system
tumors are among the most difficult to treat and lethal types of cancer (SEER, 2010). The
most common malignant brain tumor, glioblastoma, is highly invasive, rapidly growing,
and impossible to completely remove by surgery alone (Giese, 2003; Holland, 2000;
Omuro, 2013; SEER, 2010). As a result, these tumors must be treated in other ways, such
as radiation and chemotherapy (Holland, 2000; Perry, 2007; Schwartzbaum et al., 2006).
However, commonly used chemotherapeutic drugs like the DNA alkylating agents
carmustine (BCNU), lomustine (CCNU), and temozolomide (TMZ) have severe side
effects, including impaired immune system function, nausea, vomiting, hypertension, and
hematologic toxicity, such as anemia (Newlands et al., 1997; Omuro, 2013; Ransohoff et
al., 2015; Shinkaruk et al., 2003; Xiao and Link, 1998).
To improve anti-tumor treatment options, scientists are exploring natural
alternatives as treatments or adjuvants (Blažević et al., 2015; Chan et al., 2012; Choi et
al., 2010; Heshmati et al., 2013a; Ichimaru et al., 2015). One natural compound,
indirubin, is the main active ingredient in Danggui Longhui Wan, a Chinese herbal
remedy used to treat chronic myelocytic leukemia and other inflammatory diseases
(Blažević et al., 2015; Hoessel et al., 1999; Jakobs et al., 2005; Xiao et al., 2002). Natural
10

indirubin is isolated from the indigo plant, and is not very bioavailable because of its low
solubility and absorption (Blažević et al., 2015; Chan et al., 2012; Hoessel et al., 1999).
To improve bioavailability, synthetic indirubin derivatives have been synthesized
(Blažević et al., 2015; Choi et al., 2010; Heshmati et al., 2013a; Kim et al., 2011;
Polychronopoulos et al., 2004; Ribas et al., 2006). Most indirubins are thought to act
mechanistically through the aryl hydrocarbon receptor (AhR), a ligand activated
transcription factor and member of the basic-helix-basic loop pers-arnt-sims superfamily
of proteins involved in environmental sensing, cell cycle regulation, circadian rhythms,
and xenobiotic metabolism. One of the most characterized activities, and a sensitive
marker of the AhR activation, is the inductionof CYP1 family of xenobiotic metabolizing
enzyme systems associated with Phase I, II, and III processing of environmental
contaminants and endogenous ligands (Nebert et al., 2000). AhR activation has been
linked to a variety of effects, ranging from carcinogenic to chemotherapeutic, depending
on the binding strength of the ligand (Andersson et al., 2002; Koliopanos et al., 2002).
All cancer cells possess key traits in common: sustained growth signals, evasion
of growth suppressors, activation of invasion and metastasis, induction of angiogenesis,
resistance to cell death, evasion of the immune system, and the dysregulation of cellular
energetics (as reviewed by (Hanahan and Weinberg, 2011). One of the most important
aspects for the persistence of solid tumors, like glioblastoma, is the induction of
angiogenesis to promote neo-vascularization to allow blood and nutrient flow to the
otherwise hypoxic tumor center (Byrne et al., 2005; Carmeliet, 2005; Omuro, 2013).
Immune cells and their secreted products play a large role in angiogenesis in tumors,
11

much like the process seen in wound healing (Carmeliet, 2005; Coussens and Werb,
2002).
Glioblastoma patients are known to be immunocompromised in several ways
(Bodmer et al., 1989; Chamuleau et al., 2008; Ino et al., 2013; Kennedy et al., 2009;
Nishie et al., 1999; Paw et al., 2015; Ransohoff et al., 2015; Roy et al., 2014; Ryuto et al.,
1996; Sharma et al., 2005; Sica and Bronte; Ulvestad et al., 1994; Xiao and Link, 1998).
Immunosuppression due to increased regulatory T cells, anti-inflammatory cytokine
production, and decreased cytotoxic T cell activity in the tumor microenvironment has
been well documented, and is known to contribute to tumor growth and metastasis
(Bodmer et al., 1989; Letterio, 1998; Ransohoff et al., 2015; Reardon et al., 2014).
Because of this, immunotherapeutic treatment targets are currently being researched
(Kennedy et al., 2009; Mantovani et al., 2002; Nishie et al., 1999; Ransohoff et al., 2015;
Reardon et al., 2014; Sharma et al., 2005; Sica and Bronte; Ulvestad et al., 1994). One
area of interest is the polarization of macrophages and microglia, macrophage-like cells
in the CNS, to M1 or M2 phenotypes within the tumor (Mantovani et al., 2002; Nakanishi
et al., 2011; Nishie et al., 1999; Zea et al., 2005). M1 macrophages are classical
inflammatory immune cells that can actively suppress tumor cell growth through
secretion of pro-inflammatory cytokines, while M2 macrophages support tumor growth
by secreting anti-inflammatory cytokines and hindering cytotoxic T cell activity by
increasing regulatory T cell presence and downregulating antigen presentation (Kennedy
et al., 2013; Mantovani et al., 2002; Sica and Bronte; Wu et al., 2010).
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Polarization of macrophages to M1 versus M2 can be measured in their gene
expression (Mantovani et al., 2002). Prior studies have identified increased ARG2 and
IL-6 as M1 macrophages markers, and ARG1, IDO1, and IL-10 as M2 macrophage
markers (Bronte et al., 2003; Ino et al., 2013; Mantovani et al., 2002; Nakanishi et al.,
2011; Sharma et al., 2005; Zea et al., 2005). COX-2 has been suggested as a marker for
both M1 and M2 macrophages, but the M2 polarization seems to dominate in tumors
(Iachininoto et al., 2013; Minghetti, 2004; Nakanishi et al., 2011; Sharma et al., 2005;
Tjiu et al., 2009). Macrophage recruitment and polarization in the tumor
microenvironment has been shown to be impacted directly by glioblastoma cells through
the STAT3 pathway (Wu et al., 2010). The STAT3 pathway is known to be impaired by
indirubin, a natural compound isolated from the indigo plant, and synthetic indirubin
derivatives to varying degrees (Li et al., 2011; Nam et al., 2005b; Zhang et al., 2011;
Zhang et al., 2015; Zhou et al., 2009).
Indirubin and indirubin derivatives have been shown to reduce angiogenesis,
inflammation, and tumor progression (Blažević et al., 2015; Chan et al., 2012; Heshmati
et al., 2013b; Ichimaru et al., 2015; Jakobs et al., 2005; Kim et al., 2011; Nam et al.,
2005a; Zhang et al., 2011; Zhang et al., 2015). Previous studies have shown the indirubin
derivative indirubin-3’-(2,3 dihydroxypropyl)-oximether (E804) to possess
immunomodulatory and anti-angiogenic properties (Anderson, 2014; Babcock et al.,
2013; Chan et al., 2012; Ichimaru et al., 2015; Nam et al., 2005a; Nam et al., 2012;
Zhang et al., 2015). E804 has also been shown to block STAT3 signaling (Nam et al.,
2005b; Shin and Kim, 2012; Zhang et al., 2015). However, the effects of E804 on
13

angiogenesis and immunomodulation associated with glioblastoma have yet to be
evaluated. Here, I show that E804 potent inducer of CYP1B1 in T98G cells, has modest
effects on TGFβ2 secretion, and suppresses VEGF at high does, while enhancing VEGF
secretion at low doses. However, E804 could also polarize macrophages to the pro-tumor
M2 phenotype. The results of this study provide concerns with utilizing E804 as a
treatment. The anti-angiogenic effects of E804 are promising, but the concentration
would be difficult to achieve in vivo, and would need to be carefully monitored.
However, if E804 enhances immune suppression within the tumor microenvironment,
any anti-angiogenic effects may be lost or proven null. Further studies, particularly in
vivo experiments, are needed, but use of E804 to reduce angiogenesis and tumor
microenvironment immunosuppression in glioblastoma patients could be a viable option.

MATERIALS AND METHODS
Cells and Cell Culturing
The human glioblastoma cell line T98-G (American Type Culture Collection, Manassas,
Va.) was grown and maintained at 37°C with 5% CO2 in Corning 75 cm2 culture flasks,
using Dulbecco's Modified Eagle Medium (DMEM, Cellgro) supplemented with 10%
Fetal Calf Serum (FCS), 20 mM HEPES, 10 mM L-glutamine, 100 µg/ml penicillin, 100
µg/ml streptomycin, 110 µg/ml sodium pyruvate, 1% non-essential amino acids (100x
stock), and 4.5 g/L glucose. Previously published studies indicate an active AhR
signaling pathway (Gramatzki et al., 2009a).
14

Human monocyte THP-1 (American Type Culture Collection, Manassas, Va.) cells were
grown and maintained at 37°C with 5% CO2 in Corning 75 cm2 culture flasks using
DMEM (Cellgro) supplemented with 10% FCS (Atlas; Fort Collins CO), 20 mM HEPES,
10 mM L-glutamine, 100 µg/ml penicillin, 100 µg/ml streptomycin, 110 µg/ml sodium
pyruvate, 1% non-essential amino acids (100x stock), 4.5 g/L glucose, and 1.5 g/L of
NaCO3. To differentiate THP-1 cells to a macrophage phenotype, cells were pulsed with
0.1 µM phorbol myristate acetate (PMA, Alexis Chemicals) for 72 hr (Daigneault et al.,
2010; Schwende et al., 1996).
Mouse Hepa-1c1c7 cells are an AhR-active line commonly used for AhR activation and
characterization studies (Bernhard et al., 1973; Hankinson, 1995; Hankinson et al., 1991).
Cells were obtained from ATCC and maintained at 37°C with 5% CO2 in Corning 75 cm2
culture flasks using DMEM (Cellgro) supplemented with 10% FCS (Atlas; Fort Collins
CO), 20 mM HEPES, 10 mM L-glutamine, 100 µg/ml penicillin, 100 µg/ml
streptomycin, 110 µg/ml sodium pyruvate, 1% non-essential amino acids (100x stock),
4.5 g/L glucose, and 1.5 g/L of NaCO3.
Chemicals
The chemical structures of natural indirubin, E804, and TMZ are shown below in Figure
2. Indirubin-3’-(2,3 dihydroxypropyl)-oximether (E804; Alexis Biochemical, San Diego
CA) was solubilized in DMSO (Sigma Aldrich) to a stock solution of 10-2 M and stored
at -20° C. Working dilutions were made with DMEM (supplemented as previously
described) to final concentrations of 10 µM, 1 µM, and 0.1 µM. 10 µM Temozolomide
15

(TMZ; Tokyo Chemical Industry), the most common chemotherapeutic agent for
glioblastoma, was also solubilized in DMSO, and brought to working concentration in
DMEM, was used as a comparison to the activity of E804.
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(a)

(b)

(c)

Figure 2: Chemical structures of (a) natural indirubin, (b) E804, (c) TMZ.
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Cytotoxicity Assay
Viability of the cells was quantified as a function of their succinate dehydrogenase
activity, a measure of cellular respiration, by performing an MTT (3-[4,5-28
dimethylthiazol-2-yl]-2,5-diphenyltetrazolium bromide) assay. Two treatment time points
were analyzed: 6 and 24 hours. Each cell line was treated with 0.1, 1, or 10 µM E804 and
a vehicle control of DMSO. Four hours prior to the end time point, 20 μl of a 5 mg/ml
MTT solution in PBS was added to each well. At the end of the time point, wells were
aspirated and 100 μl of acidified isopropanol (4 mM HCl, 0.1% Nondet P-40 (NP40) in
isopropyl alcohol) were added to each well (Babcock et al., 2013). The plates were then
shaken for 10 minutes to disrupt cells and dissolve any remaining formazan. The optical
density of each well was then quantified at a wavelength of 550 λ. A positive control of
tributyltin (TBT) was also tested (Kergosien and Rice, 1998). Data were recorded as
optical densities and used to calculate cytotoxicity as a percentage of control treatments.
Ki-67 Labeling Index
As a secondary method to assess cell toxicity, the cellular proliferation marker Ki-67 was
used as a means to determine labeling index (Louis et al.; Montine et al., 1994). T98-G
cells were seeded in 12-well plates, and incubated for 24 hours to allow adherence. Cells
were then treated, in triplicate, with 0.1, 1, and 10 µM E804 and a vehicle control of
DMSO. At 12 and 24-hours post-treatment, media was aspirated from each well and the
cells were fixed in 0.3% formalin in PBS buffer for 15 minutes at room temperature. The
fixative was then aspirated and PBS buffer added to the wells. Cells were permeabilized
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using 0.1% Triton-X in PBS for 30 minutes at room temperature. The wells were then
incubated with non-specific antibody blocking solution (10% FBS in PBS), washed x 3 in
PBS with 0.5% tween-20 (PBS-T20), washed again x 3 with PBS-T20, then incubated
mouse anti-Ki67 (mAb 4A1, 1:1000 in PBS) primary antibody (Thermo Fisher), and then
goat anti-mouse secondary antibody conjugated with alkaline phosphatase (1:1000,
Southern Biotech), each for 1 hour. Alkaline phosphatase activity was detected using 5bromo-4-chloro-3-indolyl-phosphate (BCIP) and nitro blue tetrazolium (NBT) in alkaline
phosphatase buffer. The wells were then imaged and the number of stained cells out of
the total number of cells were counted to establish a labeling index.
CYP1B1 induction by E804 in T98G Cells
Quantitative real time PCR was then performed to measure the expression levels of
CYP1B1 following treatment with either 0.1, 1, or 10 µM E804, 10 µM DMSO carrier,
or 10 µM Temozolomide (TMZ). T98-G cells were seeded into 6-well plates and grown
to near confluence, then exposed for 6, 12, and 24-hours. Overlying media from each
well was aspirated, and cells were collected using 1 mL of RNAzol® (Molecular
Research Center, Inc.). RNA was then isolated per the manufacturer’s instructions.
cDNA was synthesized using qScript cDNA Supermix (Quanta) according to the
manufacturer’s instructions. Using primer sets listed in Table 1, qRT-PCR was
performed using the SensiFAST™ SYBR® & Fluorescein kit (BioLine) according to the
manufacturer’s instructions. Each reaction was performed in triplicate. Plates were run
and data was collected using the BioRad IQ5 detection system. Data were expressed as
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fold increase in expression compared to GAPDH house-keeping gene expression using
the Pfaffl method (Pfaffl, 2001).
Effects of E804 on Growth Factor and Cytokine Secretion
T98-G cells were grown to near confluence in T-150 flasks, then treated with either 0.1,
1, or 10 µM E804, 10 µM DMSO carrier, or 10 µM Temozolomide (TMZ). Supernatants
and cells were collected at 24 and 48 hours post treatment, then frozen at -20ºC until
ready for use. Supernatants were then analyzed by commercially available human
Cytokine Enzyme-linked Immunosorbent Assays (ELISA) kits (Biolegend, Thermo
Fisher) for IL-6, TGF-β2, VEGF, and IL-10 per the manufacturer’s instructions.
Effects of E804 on IDO1, TDO2, CYP1B1, and GAPDH Protein Expression
At the time of supernatant collection described above, cells were lysed in 1 ml of RIPA
lysis buffer (50 mM Tris HCl, pH 8, 150 mM NaCl, 1% NP-40, 0.5% sodium
deoxycholate, and 0.1% SDS) containing EDTA and protease inhibitor cocktail (Pierce)
and transferred to snap cap tubes on ice for 30 minutes. Afterward, the tubes were
vortexed again, then centrifuged at 12,000g for 10 minutes. The supernatant was then
transferred to a new 1.5 ml tube, and its protein concentration quantified. Protein
samples were diluted to a common concentration so that equal concentrations were then
run on a (4-20% SDS-PAGE) acrylamide gel, then transferred to PVDF blotting
membrane for 1 hour on ice. The PVDF blot was then incubated with non-specific
antibody blocking solution overnight at 4ºC. The following day, the blocking solution
was removed, and the PVDF blot was incubated with a targeted primary antibody for 1
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hour with gentle shaking. Primary antibodies used were goat-anti-TDO2, rabbit-antiIDO1, rabbit-anti-CYP1B1, and goat-anti-GAPDH, each diluted 1:000 in PBS. The blot
was the washed using PBS-T20 (0.05% Tween-20 in PBS buffer) 3 times for 5 minutes
with vigorous shaking. The blot was then incubated with either goat anti-rabbit IgG-AP
(1:000 in PBS, Southern Biotech) or rabbit anti-goat IgG-AP, depending on the origin
species of the primary antibody. The blot was washed again as previously described, and
alkaline phosphatase activity visualized with 5-bromo-4-chloro-3-indolyl-phosphate
(BCIP) and nitro blue tetrazolium (NBT) in alkaline phosphatase buffer. Once fully
developed, blots were rinsed with water and dried. Blots where then scanned and
analyzed via ImageJ.
Effects of Supernatants from Treated T98G Cells on Polarization of THP-1 Cells
1x106 THP-1 cells were seeded into 6-well plates and incubated for 72 hours with 0.1 µM
tetradecanoyl phorbol acetate (PMA) to differentiate them into a macrophage lineage
(Chanput et al., 2014; Garc a et al., 1999). Following differentiation and adherence,
media was removed and cells were incubated for 24 hours with 50% dilution of
supernatants from previously treated T98-G cells and fresh DMEM. Each experiment
was performed in triplicate. After incubation, cells were collected with 500 ul RNAzol
and processed for RNA and cDNA for qRT-PCR as described above. Genes of interest
were IL-6, IL-10, Arginase1, Arginase2, IDO1, and COX-2, all of which were
normalized against GAPDH. See Table 1 for primers utilized.
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Determining if T98G Supernatants Following Treatment Contain Residual AhR ligand
Activity
Hepa-1c1c7 cells were seeded into 6-well plates and grown to confluence. Cells were
then incubated for 24 hours with a 1:1 mixture of supernatants from previously treated
T98-G cells and fresh DMEM. Cells were lysed and protein concentrations were
quantified as previously described. Protein levels of CYP1B1 and GAPDH were then
measured by immunoblot as previously described.
Statistical Analysis
Comparisons of replicates were performed by ANOVA followed by Bonferroni's
multiple contrast post-hoc tests using GraphPad Prism’s statistical software. An α value
of 0.05 was established as statistically significant prior to experimentation (Fisher, 1946).
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RESULTS
MTT Assay
The T98-G cells showed no significant decrease in cellular respiration as a result of
treatment with up to 25 µM E804 for 6 or 24 hours (Figures 3 and 4). Therefore, all
studies continued to use E804 at concentrations of 0.1, 1, and 10 µM.
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Figure 3: MTT Assay, 6-hour incubation
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Figure 4: MTT Assay, 24-hour incubation
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Ki-67 Labeling Index
The protein Ki-67 is used as a marker of cellular proliferation. No significant difference
was seen in the number of Ki-67 positive T98-G cells between the treatments of 0.1, 1,
and 10 µM E804 and vehicle control of DMSO for 12 or 24 hours. Representative images
of each time point are shown below (Fig 5). Ki-67 positive cells are dark purple, while
negative cells appear clear.
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Figure 5: T98-G cells labeled with Ki-67
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CYP1B1 mRNA induction as a marker for AhR activity
To determine the strength of interaction of E804 with the aryl hydrocarbon receptor,
expression of CYP1B1, a downstream gene product of AhR activation, was measured via
qRT-PCR. CYP1B1 expression was normalized against GAPDH. A dose and timedependent response was demonstrated. The highest CYP1B1 expression difference was
seen in the 1 µM E804 treated cells, with a 5 to 10-fold change with respect to the DMSO
vehicle control (Figure 6).
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Figure 6: CYP1B1 mRNA expression in T98-G cells. Cells were treated with either
DMSO vehicle control, 0.1 µM, 1 µM, or 10 µM E804 for 6, 12, or 24-hours.
Corresponding letters above bars indicate a significant difference. (a) P ≤ 0.01, (b) P ≤
0.05, (c) P ≤ 0.0001, (d) P ≤ 0.01, (e) P ≤ 0.0001.
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Cytokine ELISAs using T98-G Supernatants
After treatment of T98-G cells with E804 and TMZ at 24 and 48 hours, the supernatants
of T98-G cells were collected. ELISAs were performed using these supernatants to
measure secretion of IL-6, TGF-β, VEGF, and IL-10. IL-6 secretion was significantly
decreased as a result of 10 µM E804 at both 24 and 48 hours (Figure 7). TGF-β secretion
was decreased at 24 hours, but increased at 48 hours at lower concentrations (Figure 8).
VEGF secretion was increased at all concentrations of E804 except 10 µM, which
significantly decreased expression (Figure 9). IL-10 secretion was not significantly
impacted (Figure 10). Corresponding letters above bars indicate significance.
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Figure 7: IL-6 secretion from T98-G cells. Cells were treated with DMSO vehicle
control, 0.1 µM, 1 µM, or 10 µM E804, or TMZ for 24- or 48-hours. Corresponding
letters above bars indicate a significant difference. (a) P ≤ 0.05, (b) P ≤ 0.01, (c) P ≤ 0.01,
(d) P ≤ 0.05, (e) P ≤ 0.001, (f) P ≤ 0.001, (g) P ≤ 0.001, (h) P ≤ 0.01.

30

500

a

400
300
200

a

100

24 hour

TM
Z

10

1

TM
Z
C
on
0.
1

10

C

1

0

on
0.
1

TGF-Beta Secretion (pg/ml)

TGF-Beta Secretion

48 hour

Figure 8: TGF-Beta secretion from T98-G cells. Cells were treated with DMSO vehicle
control, 0.1 µM, 1 µM, or 10 µM E804, or TMZ for 24- or 48-hours. Corresponding
letters above bars indicate a significant difference. (a) P ≤ 0.05.
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Figure 9: VEGF secretion from T98-G cells. Cells were treated with DMSO vehicle
control, 0.1 µM, 1 µM, or 10 µM E804, or TMZ for 24- or 48-hours. Corresponding
letters above bars indicate a significant difference. (a) P ≤ 0.05, (b) P ≤ 0.01, (c) P ≤
0.0001, (d) P ≤ 0.05, (e) P ≤ 0.0001, (f) P ≤ 0.0001, (g) P ≤ 0.05, (h) P ≤ 0.05, (i) P ≤
0.0001, (j) P ≤ 0.0001, (k) P ≤ 0.0001, (l) P ≤ 0.0001, (m) P ≤ 0.001.
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Figure 10: IL-10 secretion from T98-G cells. Cells were treated with DMSO vehicle
control, 0.1 µM, 1 µM, or 10 µM E804, or TMZ for 24- or 48-hours. No significant
differences were seen.
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Immunoblotting using T98-G Lysates
T98-G cellular lysates were collected after E804 and TMZ treatment. Western blots were
performed probing for protein expression of IDO1, TDO2, CYP1B1, and GAPDH. No
induction was seen relative to the control for any of the proteins (data not shown).
Expression of mRNAs indicative of M1 vs. M2 macrophage polarization
T98-G cellular supernatants were collected after treatment as previously described, then
applied to macrophage-like differentiated THP-1 cells for 24 hours. In this experiment,
the 24 and 48 hour groups are with respect to the treatments of T98-G cells with E804.
The mRNA expression of IL-6, Arginase 1 (ARG1), Arginase 2 (ARG2), IDO1, COX-2,
and IL-10 were quantified and normalized against GAPDH. See Table 1 for primer sets
utilized. IL-6 expression decreased in response to the 24-hour treated supernatants with
respect to a media-only control, but significantly increased in response to the 48-hour
supernatants treated with 0.1 µM E804. ARG1 expression decreased with respect to the
media-only control in response to both the 24- and 48-hour treated supernatants.
Alternatively, ARG2 expression generally increased in response to both groups. IL-10
expression initially increased in response to the 24-hour treated supernatants, particularly
the 10 µM, but decreased in response to the 48-hour treated supernatants. IDO1
expression also generally increased in response to both groups. COX-2 expression
decreased in response to the 24 hour DMSO vehicle control, 0.1, and 1 µM E804 treated
supernatants and the 48 hour 1 µM E804 treated supernatant. However, COX-2
expression increased in response to the other treated supernatants. IL-10 expression
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increased significantly in response to the 24- and 48-hour treated 10 µM E804
supernatants.
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Gene
GAPDH

Primer Sequence (5' to 3')
F: AGCCTCAAGATCATCAGCAATGCC
R: TGTGGTCATGAGTCCTTCCACGAT

Anneal Temp (°C) Product Size (bp)
57
105

COX-2

F: TACTGGAAGCCAAGCACTTT
R: GGACAGCCCTTCACGTTATT

52

92

IL-6

F: TCAATGAGGAGACTTGCCTGGTGA
R: TACTCATCTGCACAGCTCTGGCTT

58

123

IL-10

F: TCCTTGCTGGAGGACTTTAAGGGT
R: TGTCTGGGTCTTGGTTCTCAGCTT

57

109

ARG1

F: CAGGGCTACTCTCAGGATTAG
R: CCGAAACAAGCCAAGGTTATT

52

115

ARG2

F: CATGGACAGCCAGTTTCATTTC
R: CCACGTCTCTCAGACCAATATAC

52

127

IDO1

F: CACTTTGCTAAAGGCGCTGTTGGA
R: GGTTGCCTTTCCAGCCAGACAAAT

57

140

Table 1: qRT-PCR primer sets.
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Figure 11: IL-6 mRNA expression in THP-1 cells. Cells were treated with DMEM (Med
Con), or supernatants from T98-G cells treated with DMSO vehicle control, 0.1 µM, 1
µM, or 10 µM E804, or TMZ for 24- or 48-hours. Corresponding letters above bars
indicate a significant difference. (a) P ≤ 0.01, (b) P ≤ 0.05, (c) P ≤ 0.05, (d) P ≤ 0.001, (e)
P ≤ 0.01.
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Figure 12: ARG1 mRNA expression in THP-1 cells. Cells were treated with DMEM
(Med Con), or supernatants from T98-G cells treated with DMSO vehicle control, 0.1
µM, 1 µM, or 10 µM E804, or TMZ for 24- or 48-hours. Corresponding letters above
bars indicate a significant difference. (a) P ≤ 0.05.
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Figure 13: ARG2 mRNA expression in THP-1 cells. Cells were treated with DMEM
(Med Con), or supernatants from T98-G cells treated with DMSO vehicle control, 0.1
µM, 1 µM, or 10 µM E804, or TMZ for 24- or 48-hours. Corresponding letters above
bars indicate a significant difference. (a) P ≤ 0.01, (b) P ≤ 0.05, (c) P ≤ 0.05.
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Figure 14: IDO1 mRNA expression in THP-1 cells. Cells were treated with DMEM (Med
Con), or supernatants from T98-G cells treated with DMSO vehicle control, 0.1 µM, 1
µM, or 10 µM E804, or TMZ for 24- or 48-hours. Corresponding letters above bars
indicate a significant difference. (a) P ≤ 0.05.
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Figure 15: COX-2 mRNA expression in THP-1 cells. Cells were treated with DMEM
(Med Con), or supernatants from T98-G cells treated with DMSO vehicle control, 0.1
µM, 1 µM, or 10 µM E804, or TMZ for 24- or 48-hours. Corresponding letters above
bars indicate a significant difference. (a) P ≤ 0.05.
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Figure 16: IL-10 mRNA expression in THP-1 cells. Cells were treated with DMEM (Med
Con), or supernatants from T98-G cells treated with DMSO vehicle control, 0.1 µM, 1
µM, or 10 µM E804, or TMZ for 24- or 48-hours. Corresponding letters above bars
indicate a significant difference. (a) P ≤ 0.01, (b) P ≤ 0.001, (c) P ≤ 0.01, (d) P ≤ 0.05, (e)
P ≤ 0.05.
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Immunoblotting for CYP1B1 expression using Hepa-1c1c7 reporter cells
T98-G cellular supernatants were collected after E804 and TMZ treatment, and then
applied to Hepa-1c1c7 cells, which were incubated for 24 hours. Hepa-1c1c7 cellular
lysates were then collected, and Western blots performed probing for CYP1B1 and
GAPDH protein expression. No induction of CYP1B1 was seen (data not shown).

DISCUSSION
In this study, I show that basal expression of IL-6, TGF-β, and VEGF T98G cells
is extremely high, further supporting the notion that treating glioblastomas is difficult
when they are already influencing local immune responses and angiogenesis at the time
of diagnosis and first treatment. The secretion of IL-6, TGF-β, and VEGF could be
reduced by 10 µM E804, and this reduction in cytokine and growth factor secretion could
possibly lead to reduced angiogenesis. I also demonstrate that lower doses of E804
enhanced the secretion of angiogenesis-inducing VEGF, which causes concern for even
administering high doses of E804 because this indirubins in general are quickly
metabolized and eliminated (Gillam et al., 2000), thus lowering local levels to the point
of more VEGF secretion. Furthermore, E804 treatment increased the mRNA expression
levels IL-6, IDO1, COX-2, and IL-10 in THP-1 macrophages, indicating an M2
polarization. Thus, E804 may enhance immunosuppression in the tumor
microenvironment. More studies are needed, but with careful monitoring, E804 could be
a viable option to reduce angiogenesis and immunosuppression in glioblastoma patients.
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Initial cytotoxicity studies using MTT showed that E804 treatment is not affecting
cellular respiration, which is an indirect measurement of cell viability. Cells were also
labeled with Ki-67, a marker of cellular proliferation (Louis et al.; Montine et al., 1994).
After treatment, T98-G cells continued to proliferate, confirming the MTT data.
Therefore, the E804 concentrations used experimentally were not cytotoxic. Previous
studies from our lab have also shown E804’s lack of cytotoxicity on RAW264.7 murine
macrophages (Anderson, 2014).
To measure if E804 is interacting with the aryl hydrocarbon receptor (AhR), I
quantified CYP1B1 mRNA expression using qRT-PCR. The fold expression of CYP1B1
increased in a time and dose-dependent manner with E804 treatment. This suggests that
E804 is indeed interacting with the AhR and is being metabolized in the cell by the
cytochrome p450 enzyme CYP1B1 (Denison and Nagy, 2003; Spink et al., 2003). Future
studies should consider the possibility of incorporating AhR antagonist when using
chemotherapeutic agents.
Using the T98-G supernatants, ELISAs were performed to quantify IL-6, TGF-β,
VEGF, and IL-10 secretion. Previous work from our lab has shown that LPS-stimulated
RAW 264.7 macrophages secrete approximately 400 pg/ml of IL-6, so the fact that T98G glioma cells are producing around 600 pg/ml of IL-6 is considerable (Anderson, 2014).
Heightened levels of IL-6 have been implicated in increased angiogenesis and tumor
metastasis (Liu et al., 2010; Mauer et al., 2015; Taniguchi and Karin, 2014). This agrees
with other studies that have shown the anti-angiogenic properties of E804 in human
umbilical vein endothelial cells (Ali et al., 2005; Chan et al., 2012; Shin and Kim, 2012).
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TGF-β secretion increased at 48 hours in response to lower concentrations of E804 and a
slight reduction in TGF-β was seen in response to 10 µM E804 at both time points. TGFβ has been shown to suppress T-cell function in tumor cells, and increase angiogenesis
(Bodmer et al., 1989; Constam et al., 1992; Gramatzki et al., 2009b; Letterio, 1998; Wu
et al., 2010). VEGF secretion was increased at all concentrations of E804 except 10 µM,
which is cause for concern because VEGF is the main signal protein that initiates
neovascularization, which is key for solid tumors to sustain growth (Ali et al., 2005;
Byrne et al., 2005; Cabebe and Wakelee, 2007; Carmeliet, 2005; Kiselyov et al., 2007;
Shibuya, 2006; Shin and Kim, 2012; Shinkaruk et al., 2003; Zhang et al., 2011). If high
levels of E804 could be sustained, then local angiogenesis may be reduced.
The collected T98-G supernatants were also applied to differentiated macrophagelike THP-1 cells. Overall, the treated T98-G supernatants incubated with the THP-1 cells
for 24 hours generally decreased IL-6 and ARG1 expression, and increased IDO1
expression as compared to the media-only control. ARG2 and COX-2 expression did not
significantly change. For the 48-hour group, there was a general decrease in ARG1
expression, and an increase in IL-6, IDO1, ARG2, and COX-2 expression. An increase in
IL-10 expression was seen as a result of the 10 µM E804 treated T98-G supernatants at
both time points. Prior studies have identified increased ARG2 and IL-6 as M1
macrophages markers, and ARG1, IDO1, and IL-10 as M2 macrophage markers (Bronte
et al., 2003; Mantovani et al., 2002; Zea et al., 2005). COX-2 has been suggested as a
marker for both M1 and M2 macrophages, but the M2 polarization seems to dominate in
tumors (Nakanishi et al., 2011; Tjiu et al., 2009). It is difficult to tease apart individual
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effects, since there is no doubt a balancing act involved in the expression of each gene,
but with an increase in IL-6, IDO1, COX-2, and IL-10, the mRNA expression profile of
THP-1 cells treated with T98-G supernatants suggests that there is a slight M2
polarization occurring.
To confirm that there was no biologically active E804 remaining in the treated
T98-G supernatants, heap-1c1c cells were incubated with the supernatants and CYP1B1
protein levels were measured via immunoblotting. No induction of CYP1B1 was seen,
therefore, the supernatant’s effects seen on gene expression in the THP-1 qRT-PCR
results are from factors secreted into the media by the T98-G cells, and not the presence
of biologically active E804. This observation bodes well for using potent, but labile AhR
ligands as therapeutic agents in a variety of disease applications.
The results of this study suggest the E804 could have anti-angiogenic properties at
a concentration of 10 µM. However, it would be difficult to reach a concentration that
high in vivo, except perhaps with a wafer implant, such as currently used with the
chemotherapeutic drug carmustine (Gliadel®) (Perry, 2007). It is also worrisome that
lower concentrations of E804 could potentially have the opposite effects, increasing
cytokine production and angiogenesis. Another concern would be the slight M2
polarization of macrophages seen in response to E804-treated T98-G supernatants. M2
macrophages are pro-tumor and help suppress immune response the surrounding
microenvironment (Kennedy et al., 2009; Kennedy et al., 2013; Mantovani et al., 2002;
Wu et al., 2010). As a result, E804 may increase the immunosuppressive tumor
environment, enhancing tumor survival and growth. Further characterization of the
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effects of E804 is needed, particularly in vivo, but with controlled release or precise
concentration monitoring, E804 has potential as a treatment option to reduce
angiogenesis and immunosuppression in glioblastoma patients.

FUTURE EXPERIMENTS
Moving forward, there are several in vitro experiments that would help clarify the
mechanism by which E804 causes its effects. First, an experiment to knock-down or
knock-out the aryl hydrocarbon receptor would definitively prove if E804’s action was
mediated by this pathway. There are many ways to approach this type of experiment, but
the most precise method would be to use the CRISPR/Cas9 system. Next, I would
explore the nature of the immunomodulatory mechanism by which the T98-G
supernatants act on the THP-1 differentiated macrophages. It would be interesting to see
if the T98-G cells are releasing something other than cytokines and growth factors into
the media, such as extracellular vesicles. To explore this question, I would compare the
application of supernatants collected from T98-G cells to THP-1 cells to co-culturing
T98-G cells with THP-1 differentiated macrophages. Another method would be to
acquire bone-marrow derived macrophages, and use them in place of the differentiated
THP-1 cells (Weischenfeldt and Porse, 2008). Finally, I would like to explore the effect
of T98-G cells on the growth and migration of endothelial cells, such as human umbilical
vein endothelial cells. For this experiment, I would also like to compare application of
T98-G supernatants to endothelial cells with co-culturing of these two cell types.
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After further in vitro characterization, I would move into an in vivo mouse model
to compare to the in vitro results, in order to see if E804 could perform in a similar way
in a live organism. To do this, I would want to first use an immunocompromised mouse
model with a xenograft human glioma, such as U251 or U1242 MG, to look at
angiogenesis, growth, and metastasis (Chen et al., 2013; Pontén, 1975; Zhao et al., 2010).
To see the effect of E804 on immunomodulation in vivo, I would use adult mice or rats
with an active immune system in which the formation of glioma-like tumors were
initiated using a retrovirus, such as described in other studies (Assanah et al., 2006;
Kamiyama et al., 2005; Kennedy et al., 2009; Uhrbom et al., 1998).
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